In Vivo Star Anti-Mouse CD279 (PD1) / VEGFR-2 Bispecific Antibody
英诺赛图(InnoCyto)的 In Vivo Star Anti-Mouse CD279 (PD1) / VEGFR-2 Bispecific Antibody(克隆 RMP1-14 / DC101) 为鼠源 IgG2c LALAPG Kappa 抗体,靶向 Mouse,适用于功能实验。提供 1 mg、5 mg、25 mg 规格,目录价 ¥11,865 起,仅供科研使用(RUO)。
01产品图片

02产品简介
英诺赛图(InnoCyto)的 In Vivo Star Anti-Mouse CD279 (PD1) / VEGFR-2 Bispecific Antibody(克隆 RMP1-14 / DC101) 为鼠源 IgG2c LALAPG Kappa 抗体,靶向 Mouse,适用于功能实验。提供 1 mg、5 mg、25 mg 规格,目录价 ¥11,865 起,仅供科研使用(RUO)。
03产品介绍
规格与货号
514901 | 1 mg | ¥11,865
514902 | 5 mg | ¥40,341
514903 | 25 mg | ¥121,023
515001 | 1 mg | ¥11,865
515002 | 5 mg | ¥40,341
515003 | 25 mg | ¥121,023
Product Details
Target Name|PD1, PD-1, PDCD1, CD279, SLEB2, VEGFR2, VEGF-R2, KDR, Tyrosin kinase growth factor receptor, homolog of FLK1 (FLK1), VEGFR
Product Description|In Vivo Grade Recombinant Anti-mouse PD-1 / VEGFR-2 Bispecific Antibody
Regulatory Status|RUO
Endotoxin
Storage Conditions|4ºC
Recommended Usage|This product is suitable for in vivo animal use. Optimal amounts need to be determined empirically for each experiment.
See All Formats|Clone RMP1-14 / DC101
Background Information
Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor expressed primarily on activated T cells, B cells, and some myeloid cells. It plays a crucial role in regulating immune responses by maintaining peripheral tolerance and preventing autoimmunity. When PD-1 binds to its ligands PD-L1 or PD-L2 on antigen-presenting or tumor cells, it recruits SHP-2 phosphatase, which dephosphorylates key signaling molecules in the T cell receptor (TCR) pathway. This suppresses T cell proliferation, cytokine secretion, and cytotoxic activity. In cancer, chronic PD-1 engagement results in “T cell exhaustion,” allowing tumor cells to evade immune destruction. Therapeutic blockade of PD-1 with monoclonal antibodies such as nivolumab or pembrolizumab reactivates these T cells, enabling potent anti-tumor immune responses.
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), also known as KDR (kinase insert domain receptor) or Flk-1, is the principal receptor mediating the angiogenic effects of VEGF-A. VEGFR2 is expressed mainly on endothelial cells and functions as a receptor tyrosine kinase. Upon VEGF-A binding, VEGFR2 dimerizes and becomes autophosphorylated, initiating downstream signaling pathways such as MAPK, PI3K-Akt, and PLCγ, which drive endothelial cell proliferation, migration, and new vessel formation. In tumors, overactivation of VEGFR2 results in aberrant angiogenesis, leading to structurally and functionally abnormal vasculature that not only sustains tumor growth and metastasis but also creates an immunosuppressive microenvironment by limiting immune cell infiltration and promoting hypoxia.
A bispecific antibody targeting PD-1 and VEGFR2 would provide a synergistic approach to enhancing anti-tumor immunity. By simultaneously blocking PD-1, the antibody would reinvigorate exhausted cytotoxic T cells, restoring their ability to recognize and kill tumor cells. Concurrent inhibition of VEGFR2 signaling would normalize the tumor vasculature, reduce hypoxia, and improve the trafficking of activated T cells into the tumor microenvironment. Moreover, suppressing VEGF/VEGFR2-mediated immunosuppression would shift the tumor milieu toward a more pro-inflammatory and immune-permissive state. This dual mechanism could overcome resistance observed with single-agent checkpoint inhibitors or anti-angiogenic therapies alone. Additionally, combining checkpoint modulation and vascular normalization into a single molecule may optimize pharmacokinetics, enhance co-localization within the tumor, and reduce toxicity relative to combination regimens. Thus, a PD-1 × VEGFR2 bispecific antibody represents a promising next-generation immunotherapy platform capable of simultaneously activating immune effector cells and dismantling the physical and molecular barriers that protect tumors from immune attack.
Data Sheets
Cat # Size Price Quantity 5149011 mg Add to Cart5149025 mg Add to Cart51490325 mg Add to Cart
04完整参数表
参数由厂商资料整理,采购前请以最终报价单与技术协议为准。
05荣誉与资质
该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。
- 营业执照未上传
- 品牌授权未上传
- 产品检测报告未上传
- 会员身份
- 收费会员
- 经营身份
- 原厂
- 成立年份
- 2020 年
- 所在地
- 上海
- 收录条目
- 1865 个
- 平台核验
- 平台代管
06品牌与供应商
InnoCyto(上海英诺赛图生物科技有限公司)致力于通过开发高质量细胞分析试剂,加速科学发现进程。公司为研究人员提供细胞层面探索所需的工具,推动免疫学、肿瘤学等多领域的研究创新。 核心团队拥有丰富的行业经验,曾参与全球头部生命科学公司的标杆项目搭建,深刻理解工业界与学术研究的前沿需求。试剂从设计之初即以精确性、一致性、高性能为核心标准,让科学家能把精力集中在最核心的研究工作上。 公司将深厚的科学积累与对品质的严格承诺相结合,力争成为全球研究人员信赖的合作伙伴。产品线覆盖经验证的一抗与二抗、同型对照、生物类似药抗体、重组蛋白、细胞因子、免疫检测试剂盒及配套试剂,并提供重组蛋白/抗体表达与标记偶联服务。
品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。
07同类条目
同一子类内的条目才具备可比性。跨子类比较参数通常没有意义。
08同品牌其他条目
上海英诺赛图 在本目录共 1865 个条目,除本条外还有:
科研在线(TeleVM). In Vivo Star Anti-Mouse CD279 (PD1) / VEGFR-2 Bispecific Antibody(514901)[EB/OL]. 产品目录, 2026-11-12. https://www.suprotek.cn/products/item/in-vivo-star-anti-mouse-cd279-pd1-vegfr-2-bispecific-antibod.html.
TeleVM. (2026, November 12). In Vivo Star Anti-Mouse CD279 (PD1) / VEGFR-2 Bispecific Antibody(514901). 产品目录. https://www.suprotek.cn/products/item/in-vivo-star-anti-mouse-cd279-pd1-vegfr-2-bispecific-antibod.html
@misc{biocsp_item_in_vivo_star_anti_mouse_cd279_pd1_vegfr_2_bispecific_antibod,
title = {In Vivo Star Anti-Mouse CD279 (PD1) / VEGFR-2 Bispecific Antibody(514901)},
author = {{科研在线}},
year = {2026},
howpublished = {产品目录},
note = {更新于 2026-11-12,产品目录},
url = {https://www.suprotek.cn/products/item/in-vivo-star-anti-mouse-cd279-pd1-vegfr-2-bispecific-antibod.html}
}
GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。
许可:CC BY-NC 4.0 · 转载注明来源